Eledon Submits Islet Cell IND for Tegoprubart

Eledon Pharmaceuticals' parallel IND strategy for tegoprubart is now stress-testing the regulatory and clinical boundaries of novel immunosuppression across four simultaneous transplant programs, a structural complexity that QA directors and regulatory affairs leads at investigational sites will need to track closely. The Irvine-based company submitted an Investigational New Drug (IND) application to the FDA for a Company-sponsored, registrational study of tegoprubart in pancreatic islet cell transplantation for type 1 diabetes patients, while confirming its global Phase 3 LEGACY trial in kidney transplantation remains on schedule for Q4 2026 initiation.

Tegoprubart is an anti-CD40L antibody under evaluation as a calcineurin inhibitor–free immunosuppression regimen. The clinical rationale across programs centers on tacrolimus toxicity: calcineurin inhibitor–related renal dysfunction has historically constrained islet cell transplantation, and Eledon is using both investigator-initiated trials and compassionate-use protocols to generate data in populations where that constraint is most acute.

Four distinct clinical activities are now running concurrently. First patients have been enrolled in an investigator-initiated study at the University of Chicago Medicine Transplant Institute, evaluating tegoprubart in islet cell transplant recipients with type 1 diabetes and chronic kidney disease. Separately, the first islet cell transplant recipient has been dosed under a compassionate-use protocol following conversion from tacrolimus due to calcineurin inhibitor–related kidney dysfunction. A fourth program has dosed first patients under compassionate use in highly sensitized kidney transplant recipients carrying pre-existing donor-specific antibodies, a population with elevated immunologic risk and limited immunosuppression options.

For regulatory affairs teams, the architecture here is notable: compassionate use is functioning as a structured data-generation mechanism alongside formal IND-governed studies, a pattern that requires rigorous pharmacovigilance alignment and CAPA-ready safety monitoring across sites. Investigator-initiated studies introduce additional protocol governance considerations, particularly where site-level GMP compliance and 21 CFR Part 312 obligations intersect with sponsor oversight responsibilities.

Eledon has indicated that all four programs are expected to generate clinical data updates within the next 12 months, a timeline that runs directly into the anticipated LEGACY Phase 3 enrollment window and will inform the immunosuppression protocol design underpinning that registrational trial.

The measurable checkpoint ahead is LEGACY trial initiation in Q4 2026, against which the IND acceptance status for the islet cell registrational study will serve as a parallel regulatory indicator of the program's trajectory.

Source: Eledon Pharmaceuticals via GlobeNewswire, September 3, 2026.